Skip to content

A prospective randomized controlled trial of a new method for glucocorticoid intervention in progressive IgA nephropathy

A prospective randomized controlled trial of a new method for glucocorticoid intervention in progressive IgA nephropathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026883
Enrollment
Unknown
Registered
2019-10-25
Start date
2019-12-01
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

1:0.5mg/kg.d prednisolone induced remission
2:0.8mg/kg.d prednisolone induced remission

Sponsors

Nephrology Department, Hangzhou Hospital of Traditional Chinese Medicine, Zhejiang Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 72 Years

Inclusion criteria

Inclusion criteria: 1. Renal biopsy confirmed IgAN patients; 2. Aged 18-72 years, gender is not limited; 3. After the maximum tolerated dose of RAS blocker (addition of other antihypertensive drugs when not ineffective), the urine protein (most recently examined) after treatment is between 1.0g and 3.5g/day; 4. eGFR (last inspection): 30 - 120ml/min·1.73m2 (inclusive).

Exclusion criteria

Exclusion criteria: 1. Indications for the use of intensive glucocorticoids for immunosuppressive therapy, such as: nephrotic syndrome with minimal pathology and IgAN, and a proportion of crescents confirmed by renal biopsy within 12 months >50%; 2. Contraindications for immunosuppressive therapy using glucocorticoids, including infections, tuberculosis, malignant tumors, pregnant and lactating patients, etc.; 3. Received immunosuppressive therapy in the past 1 year; 4. Malignant or uncontrolled hypertension (systolic blood pressure > 160mm or diastolic blood pressure > 110mmHg); 5. Have clear secondary causes, such as autoimmune diseases, cirrhosis and other secondary IgA nephropathy; 6. Poor compliance, not with treatment; 7. Participate in other clinical studies (involved or participated in the previous month).

Design outcomes

Primary

MeasureTime frame
Reduction of eGFR>40%, renal replacement therapy, ESRD;

Secondary

MeasureTime frame
Glomerular filtration rate;Urinary protein creatinine ratio;24h urine protein quantitation;Blood uric acid;

Countries

China

Contacts

Public ContactBin Zhu

Nephrology Department, Hangzhou Hospital of Traditional Chinese Medicine, Zhejiang

zhubing@hotmail.com+86 15888826243

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026